Perceptronix - Early Diagnosis, Better Outcomes
   
  New Perceptronix Medical Inc. test for early-stage oral cancer demonstrated at Pacific Dental Conference  
  Perceptronix featured at BioPartnering North America  
  Kelowna Figures Prominently in Lung Cancer Research  
     

Perceptronix Medical Inc. is a Vancouver-based, privately-owned cancer diagnostic company founded in June 1999 as a spin off of the BC Cancer Agency. The Company’s mission is to commercialize effective technologies to improve the early detection, localization, diagnosis and follow-up of cancer, with an initial focus on lung cancer. This disease has reached epidemic proportions and typically has a poor outcome (five year survival rate is less than 15%) because symptoms are not usually present until the disease is in an advanced stage.

Early detection of cancer offers cancer patients the best hope for a favourable outcome. Perceptronix products and services offer an improvement over existing detection and localization technologies and provide physicians with increased options for prolonging and improving the quality of patients’ lives.

s    
 
 
 

Lung Cancer Risk Assessment Test

 
  s  
 
 
   
  s  
 
ClearCyte™
 
s

Advanced Cytopathology